IsoRay (ISR) Stock Climbs On Cesium-131 Data

IsoRay, Inc. (NYSEMKT: ISR)

IsoRay is having an incredible day in the market after publishing a recent peer-reviewed Cesium-131 study result. Today, we’ll talk about the results of the recent study, how the market is reacting to the news, and what we can expect to see from ISR moving forward.

ISR Publishes Positive Data

In a publication titled “Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial”, ISR has published incredibly positive data with regard to Cesium-131. According to the publication, ISR treated 24 patients that had newly diagnosed metastasis to the brain with Cesium-131 brachytherapy seeds after surgical resection. The treatments took place between 2010 and 2012. Before treatment, a physician administered mini-mental status examinations and functional assessment of cancer brain therapy before treatment, every 2 months for a 6-month period following treatment, and at the end of a 12 month period. According to the published results, the study found that surgical resection with Cesium-131 brachytherapy is able to stabilize and improve neurocognitive function for patients with metastatic brain tumors. It goes without saying that this is incredibly good news for ISR and its investors. In a statement Isoray’s Chairman and CEO, Dwight Babcock had the following to say:

This study suggests that surgical resection with intraoperative CS-131 has the capacity to preserve or even improve quality of life after treatment in the short-term. This is encouraging and we look forward to the results of a comprehensive, longitudinal multi-center study, which is currently underway. We thank Weil Cornell Medical College and the authors of this study for their ongoing work in cancer research and Cs-131’s potential applications.”

How The Market Reacted To The News

Historically, when positive news comes out surrounding a publicly traded company, we tend to see gains in the stock as a result. That’s exactly what we’re seeing from ISR today in the market. Currently (10:10), ISR is trading at $1.08 per share after a gain of 5.88%.

What We Can Expect To See Moving Forward

The data that was released today with regard to Cesium-131 was overwhelmingly positive, giving investors good reason to be excited. When I first heard about the treatment, I was eager to see what would happen next. After all, the radioactive half life of this treatment is incredibly short. This means that patients’ family and friends aren’t in radioactive danger when spending time with the patient. Now, as more and more data is released, showing incredibly positive signs, I’m becoming more and more excited to see what’s going to happen next. With that said, I’m impressed with ISR. While it may take some time for the company to become a major player in biotech, they are clearly moving things in the right direction; So, I’m expecting to see growth out of the company in the long run.

What Do You Think?

Where do you think ISR is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

 

Trade With A CNA Finance Trusted Broker
Broker Trade Fees Promotion Sign Up Here
TradeKing $4.95
Firstrade $6.95
TradeStation $9.99 Open a TradeStation Account!

Add Comment